Health and industrial sciences company PerkinElmer Inc. said
Thursday that it agreed to buy CambridgeSoft Corp. and that it has bought
ArtusLabs.

The cumulative purchase price for the companies, which
provide software for the pharmaceutical industry, is about $220 million plus a
potential $15 million more through a contingent consideration, PerkinElmer
said.

In a statement, PerkinElmer CEO Robert Friel said
CambridgeSoft will add “strong customer relationships and excellent
organizational capability, along with market leading products in both desktop
and enterprise-wide software.” ArtusLabs gives PerkinElmer
“innovative technology enabling enhanced access to scientific
knowledge,” he said, that will complement CambridgeSoft’s informatics
offerings.

PerkinElmer expects the two companies to have combined
revenue of $65 million this year. It said the acquisitions will lower its
profit by 13 cents per share for 2011, but on an adjusted basis it will add 4
cents per share to its earnings for the rest of the year.

PerkinElmer expects to finish the CambridgeSoft acquisition
during the second quarter.